NO20043833L - Anvendelse av en kombinasjon av forbindelser med partiell dopamin D2 reseptoragonistaktivitet samt serotonin- og/eller noradrenalininhibitoraktivitet til behandling av psykiatriske eller neurologiske forstyrrelser. - Google Patents

Anvendelse av en kombinasjon av forbindelser med partiell dopamin D2 reseptoragonistaktivitet samt serotonin- og/eller noradrenalininhibitoraktivitet til behandling av psykiatriske eller neurologiske forstyrrelser.

Info

Publication number
NO20043833L
NO20043833L NO20043833A NO20043833A NO20043833L NO 20043833 L NO20043833 L NO 20043833L NO 20043833 A NO20043833 A NO 20043833A NO 20043833 A NO20043833 A NO 20043833A NO 20043833 L NO20043833 L NO 20043833L
Authority
NO
Norway
Prior art keywords
activity
serotonin
compounds
combination
well
Prior art date
Application number
NO20043833A
Other languages
English (en)
Norwegian (no)
Inventor
Gustaaf Johan Mar Scharrenburg
Roelof W Feenstra
Eric Ronken
Andrew C Mccreary
Juliana B Bronzova
Jeffrey C Giennon
Jan Van Randen
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20043833L publication Critical patent/NO20043833L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20043833A 2002-02-14 2004-09-13 Anvendelse av en kombinasjon av forbindelser med partiell dopamin D2 reseptoragonistaktivitet samt serotonin- og/eller noradrenalininhibitoraktivitet til behandling av psykiatriske eller neurologiske forstyrrelser. NO20043833L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20020076344 EP1336406A1 (en) 2002-02-14 2002-02-14 Partial dopamine-D2 receptor agonist plus serotonin and/or noradrenaline inhibitory activity
PCT/EP2003/050015 WO2003068207A2 (en) 2002-02-14 2003-02-11 Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity

Publications (1)

Publication Number Publication Date
NO20043833L true NO20043833L (no) 2004-09-13

Family

ID=27619173

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043833A NO20043833L (no) 2002-02-14 2004-09-13 Anvendelse av en kombinasjon av forbindelser med partiell dopamin D2 reseptoragonistaktivitet samt serotonin- og/eller noradrenalininhibitoraktivitet til behandling av psykiatriske eller neurologiske forstyrrelser.

Country Status (16)

Country Link
US (1) US20050038015A1 (enExample)
EP (2) EP1336406A1 (enExample)
JP (1) JP2005517036A (enExample)
KR (1) KR20040081779A (enExample)
CN (1) CN1592614A (enExample)
AU (1) AU2003208714A1 (enExample)
BR (1) BR0306147A (enExample)
CA (1) CA2462688A1 (enExample)
HR (1) HRP20040276A2 (enExample)
IL (1) IL160942A0 (enExample)
MX (1) MXPA04004745A (enExample)
NO (1) NO20043833L (enExample)
PL (1) PL370632A1 (enExample)
RU (1) RU2004112546A (enExample)
WO (1) WO2003068207A2 (enExample)
ZA (1) ZA200404740B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ517900A (en) 1999-08-23 2003-08-29 Solvay Pharm Bv Phenylpiperazines useful as serotonin reuptake inhibitors
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
AR032712A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
AR032711A1 (es) 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
US7504395B2 (en) * 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
AR042806A1 (es) * 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
WO2004060374A1 (en) 2002-12-27 2004-07-22 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
GB0327195D0 (en) * 2003-11-21 2003-12-24 Smithkline Beecham Corp Novel use
EP1595542A1 (en) * 2004-03-26 2005-11-16 Solvay Pharmaceuticals B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
US7596407B2 (en) 2004-03-26 2009-09-29 Solvay Pharmaceuticals, B.V. Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds
WO2007019880A1 (en) * 2005-08-18 2007-02-22 Inserm (Institut National De La Sante Et De La Recherche Medicale) Use of a selective inhibitor of norepinephrine reuptake for treating respiratory disorders resulting from rett syndrome
WO2007065713A2 (en) * 2005-12-08 2007-06-14 Axxonis Pharma Gmbh Use of 8-alpha-ergolines for the treatment of traumatic brain disorders
EP2457571A1 (en) 2007-02-01 2012-05-30 Alan I. Green Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
NZ583193A (en) * 2007-07-23 2012-05-25 Biotie Therapies Inc Treatment of post-traumatic stress disorder with nepicastat
TW200936130A (en) * 2008-02-26 2009-09-01 Lundbeck & Co As H Uses of indane compounds
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
KR20130103662A (ko) * 2010-04-19 2013-09-24 엔라이프 떼라퓨틱스, 에스.엘. 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법
CN111134894B (zh) * 2020-01-17 2022-02-22 上海长海医院 一种在体测定犬前列腺组织连续动态游离药物浓度的采样方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71590C2 (en) * 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
NZ517900A (en) * 1999-08-23 2003-08-29 Solvay Pharm Bv Phenylpiperazines useful as serotonin reuptake inhibitors

Also Published As

Publication number Publication date
CN1592614A (zh) 2005-03-09
EP1476148A2 (en) 2004-11-17
WO2003068207A2 (en) 2003-08-21
EP1336406A1 (en) 2003-08-20
RU2004112546A (ru) 2005-03-27
ZA200404740B (en) 2005-08-23
AU2003208714A1 (en) 2003-09-04
JP2005517036A (ja) 2005-06-09
CA2462688A1 (en) 2003-08-21
KR20040081779A (ko) 2004-09-22
IL160942A0 (en) 2004-08-31
PL370632A1 (en) 2005-05-30
US20050038015A1 (en) 2005-02-17
HRP20040276A2 (en) 2005-04-30
MXPA04004745A (es) 2004-08-02
BR0306147A (pt) 2004-10-19
WO2003068207A3 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
AP2001002252A0 (en) Monoamine reuptake inhibitors for treatment of CNS disorders.
WO2004047830A3 (de) Pharmazeutische zusammensetzung aus einem beta-3-adrenozeptor-agonisten und einem serotonin- und/oder norepinephrin-reuptake-inhibitor deren verwendung zur behandlung von blasenfunktionsstörungen
NO20120150L (no) Bifenylderivat, farmasoytisk sammensetning omfattende samme samt anvendelse av samme til behandling av en pulmonal lidelse
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
PH12012501514A1 (en) (2s, 3r)-n-(2-((3-pyridinyl)methyl)-1-azabycyclo[2.2.2]oct-3-yl)benzofuran-2-carboxamide, novel salt forms, and methods of use thereof
ZA200509542B (en) Combination of an NDMA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
PT1666462E (pt) Derivados de n-[1h-indol-5-il]-naftaleno-1-sulfonamida e compostos associados enquanto antagonistas do receptor 5- ht6 de serotonina para o tratamento de distúrbios do sistema nervoso central
NL1026044A1 (nl) Inwendige roterende regelkop voor stijgbuis.
WO2003068207A3 (en) Partial dopamine-d2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
PL1833799T3 (pl) 3-Fenylo-pirazolowe pochodne jako modulatory 5-HT2A receptora serotoniny użyteczne w leczeniu zaburzeń związanych z tym receptorem
WO2006014918A3 (en) Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
IS2907B (is) Bensó[d]asepínafleiður til að meðhöndla taugakvilla
ATE542816T1 (de) Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
IL178648A0 (en) Substituted morpholine compounds for the treatment of central nervous system disorders
IL189298A0 (en) 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission
WO2007108936A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2010120695A3 (en) 5-ht4 receptor agonist compounds for treatment of cognitive disorders
BRPI0511527A (pt) compostos e composições como moduladores de ppar
ZA200703060B (en) Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to odulation of the dopamine d3 receptor
WO2004052858A3 (en) Inhibitors of monoamine uptake
NO20055098D0 (no) Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser
WO2005048932A3 (en) N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
ZA200509169B (en) Method of treating or preventing central nervous system disorders with compounds having selectivity for the alpha 3 subunit of the benzodiazepine receptor
IS8388A (is) Blandan af serótónín endurupptökuhindra og histamín 3 viðtaka mótlyfi, öflugum verka eða hlutaverka